<?xml version="1.0" encoding="UTF-8"?><rss xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:content="http://purl.org/rss/1.0/modules/content/" xmlns:atom="http://www.w3.org/2005/Atom" version="2.0" xmlns:media="http://search.yahoo.com/mrss/"><channel><title><![CDATA[Reviews for Techies]]></title><description><![CDATA[Thoughts, stories and ideas.]]></description><link>https://fahad.focalize.md/</link><image><url>https://fahad.focalize.md/favicon.png</url><title>Reviews for Techies</title><link>https://fahad.focalize.md/</link></image><generator>Ghost 4.19</generator><lastBuildDate>Sun, 12 Apr 2026 06:17:38 GMT</lastBuildDate><atom:link href="https://fahad.focalize.md/rss/" rel="self" type="application/rss+xml"/><ttl>60</ttl><item><title><![CDATA[Life's Simple 7 Cardiovascular Health Score in Relation to Arrhythmias on Extended Ambulatory Electrocardiographic Monitoring (from the Multi-Ethnic Study of Atherosclerosis).]]></title><description><![CDATA[<p><strong>Must read!!!</strong></p><p></p><p><strong><u>JOURNAL</u></strong><br>The American journal of cardiology</p><p><strong><u>DOI</u></strong><br>10.1016/j.amjcard.2022.01.028</p><p><strong><u>Author(s)</u></strong><br>Ma|Yuyang|Y|;Floyd|James S|JS|;Austin|Thomas R|TR|;Chen|Lin Yee|LY|;Horwich|Tamara|T|;Post|Wendy S|WS|;Michos|Erin D|ED|;Heckbert|Susan R|SR|</p><p><strong><u>Abstract</u></strong><br>The</p>]]></description><link>https://fahad.focalize.md/lifes-simple-7-cardiovascular-health-score-in-relation-to-arrhythmias-on-extended-ambulatory-electrocardiographic-monitoring-from-the-multi-ethnic-study-of-atherosclerosis/</link><guid isPermaLink="false">6267d4d950d08c0448eec0f2</guid><dc:creator><![CDATA[Fahad Shahid]]></dc:creator><pubDate>Tue, 26 Apr 2022 11:19:14 GMT</pubDate><content:encoded><![CDATA[<p><strong>Must read!!!</strong></p><p></p><p><strong><u>JOURNAL</u></strong><br>The American journal of cardiology</p><p><strong><u>DOI</u></strong><br>10.1016/j.amjcard.2022.01.028</p><p><strong><u>Author(s)</u></strong><br>Ma|Yuyang|Y|;Floyd|James S|JS|;Austin|Thomas R|TR|;Chen|Lin Yee|LY|;Horwich|Tamara|T|;Post|Wendy S|WS|;Michos|Erin D|ED|;Heckbert|Susan R|SR|</p><p><strong><u>Abstract</u></strong><br>The Life&apos;s Simple 7 (LS7) metric consists of 7 modifiable health behaviors and measures that are known health factors for cardiovascular wellness. Relatively little is known about the association of LS7 score with cardiac arrhythmias. In the setting of the Multi-Ethnic Study of Atherosclerosis, we studied the LS7 score (range 0 to 14), assessed at the 2010 to 2102 study visit, in relation to cardiac arrhythmias assessed by Zio Patch ambulatory electrocardiographic monitoring in 2016 to 2018. In participants free of clinically recognized cardiovascular disease and atrial fibrillation, we used logistic and linear regression to examine the association of total LS7 score with atrial fibrillation, supraventricular ectopy, and ventricular ectopy. In 1,329 participants in the analysis, the mean (SD) age was 67 (8) years and 48% were men. A more favorable total LS7 score was associated with fewer premature ventricular contractions (PVCs) per hour (ratio of geometric means for optimal [11 to 14] versus inadequate [0 to 7] score 0.52 [95% confidence interval 0.34 to 0.81]). After adjustment for sociodemographic characteristics, the association was attenuated (0.66 [0.43 to 1.01]). =Among the LS7 components, a more favorable body mass index was associated with less ventricular ectopy. We did not detect associations of total LS7 score with atrial arrhythmias. In conclusion, in this longitudinal study of older participants free of clinically recognized cardiovascular disease, there was little evidence of association of the LS7 cardiovascular health score with subclinical cardiac arrhythmias. However, there was a suggestion that a more favorable LS7 score was associated with fewer PVCs and specifically, that a more favorable body mass index was associated with fewer PVCs.</p><p><a href="https://www.focalize.md/find-journals/?a=QdjlK4ABjZS8LUbgRBfY">https://www.focalize.md/find-journals/?a=QdjlK4ABjZS8LUbgRBfY</a></p>]]></content:encoded></item><item><title><![CDATA["What are my chances of developing COPD if one of my parents has the disease?" A systematic review and meta-analysis of prevalence of co-occurrence of COPD diagnosis in parents and offspring]]></title><description><![CDATA[<p>This is ss</p><p></p><p><strong><u>JOURNAL</u></strong><br>International journal of chronic obstructive pulmonary disease</p><p><strong><u>DOI</u></strong><br>10.2147/COPD.S123933</p><p><strong><u>Author(s)</u></strong><br>Li|Lok Sze Katrina|LS|;Paquet|Catherine|C|;Johnston|Kylie|K|;Williams|Marie T|MT|</p><p><strong><u>Abstract</u></strong><br>INTRODUCTION Intergenerational associations in chronic obstructive pulmonary disease (COPD) have been well recognized and may result</p>]]></description><link>https://fahad.focalize.md/what-are-my-chances-of-developing-copd-if-one-of-my-parents-has-the-disease-a-systematic-review-and-meta-analysis-of-prevalence-of-co-occurrence-of-copd-diagnosis-in-parents-and-offspri-2/</link><guid isPermaLink="false">624ae7f74453f9d5115902e0</guid><dc:creator><![CDATA[Fahad Shahid]]></dc:creator><pubDate>Mon, 04 Apr 2022 12:45:26 GMT</pubDate><content:encoded><![CDATA[<p>This is ss</p><p></p><p><strong><u>JOURNAL</u></strong><br>International journal of chronic obstructive pulmonary disease</p><p><strong><u>DOI</u></strong><br>10.2147/COPD.S123933</p><p><strong><u>Author(s)</u></strong><br>Li|Lok Sze Katrina|LS|;Paquet|Catherine|C|;Johnston|Kylie|K|;Williams|Marie T|MT|</p><p><strong><u>Abstract</u></strong><br>INTRODUCTION Intergenerational associations in chronic obstructive pulmonary disease (COPD) have been well recognized and may result from genetic, gene environment, or exposure to life course factors. Consequently, adult offspring of parents with COPD may be at a greater risk of developing COPD. The aim of this study was to review the prevalence of co-occurrence of COPD in adult offspring with one or both parents having COPD independent of specific genetic variations. METHODS In total, five databases were searched for original studies in which prevalence of COPD was reported in both offspring (children) and one or both parents. Studies were excluded if COPD was not clearly defined, COPD was linked to specific genetic variations, COPD was combined with other chronic respiratory conditions, or estimates included other first-degree relatives. Data extraction (ie, sample characteristics, prevalence of COPD, and odds ratio [OR] if reported) was completed by two independent reviewers. A meta-analysis of prevalence and OR was conducted, where possible. RESULTS Of the 3,382 citations, 129 full texts were reviewed to include eight studies (six case-control, one cross-sectional, and one cohort) reflecting either prevalence of COPD in offspring of parents with COPD (descendent approach, n=3), which ranged from 0% to 17.3%, or prevalence of people with COPD reporting positive parental history of COPD (antecedent approach, n=5), for which the pooled prevalence was 28.6%. Offspring of people with COPD had 1.57 times greater odds (95% confidence interval =1.29-1.93; P&lt;0.001) of having COPD compared with people not having a parental history of COPD. CONCLUSION The prevalence of COPD in adult offspring of people with COPD is greater than population-based estimates, and the ORs indicate a higher risk in this group. This offers clinicians a potential strategy for opportunistic screening, early identification, and intervention in this at-risk group.</p><p><a href="https://www.focalize.md/find-journals/?a=EQlgO3wBEtb5a2zzWs0T">https://www.focalize.md/find-journals/?a=EQlgO3wBEtb5a2zzWs0T</a></p>]]></content:encoded></item><item><title><![CDATA[The Path to Better Understanding Heart Failure Epidemiology.]]></title><description><![CDATA[<p></p><p>this is really..</p><p></p><p><strong><u>JOURNAL</u></strong><br>Journal of the American College of Cardiology</p><p><strong><u>DOI</u></strong><br>10.1016/j.jacc.2021.11.025</p><p><strong><u>Author(s)</u></strong><br>Fontes|Jo&#xE3;o D|JD|;Massera|Daniele|D|</p><p><strong><u>Abstract</u></strong><br></p><p><a href="https://www.focalize.md/find-journals/?a=AExhtX4BEtb5a2zzHlYW">https://www.focalize.md/find-journals/?a=AExhtX4BEtb5a2zzHlYW</a></p>]]></description><link>https://fahad.focalize.md/the-path-to-better-understanding-heart-failure-epidemiology/</link><guid isPermaLink="false">61fbcf48497938a002e193c4</guid><dc:creator><![CDATA[Fahad Shahid]]></dc:creator><pubDate>Thu, 03 Feb 2022 12:51:30 GMT</pubDate><content:encoded><![CDATA[<p></p><p>this is really..</p><p></p><p><strong><u>JOURNAL</u></strong><br>Journal of the American College of Cardiology</p><p><strong><u>DOI</u></strong><br>10.1016/j.jacc.2021.11.025</p><p><strong><u>Author(s)</u></strong><br>Fontes|Jo&#xE3;o D|JD|;Massera|Daniele|D|</p><p><strong><u>Abstract</u></strong><br></p><p><a href="https://www.focalize.md/find-journals/?a=AExhtX4BEtb5a2zzHlYW">https://www.focalize.md/find-journals/?a=AExhtX4BEtb5a2zzHlYW</a></p>]]></content:encoded></item><item><title><![CDATA[Outcomes of Direct Oral Anticoagulants Co-Prescribed with Common Interacting Medications.]]></title><description><![CDATA[<p><strong><u>JOURNAL</u></strong><br>The American journal of cardiology</p><p><strong><u>DOI</u></strong><br>10.1016/j.amjcard.2021.09.025</p><p><strong><u>Author(s)</u></strong><br>D Sanborn;A Sugrue;M Amin;R Mehta;M Farwati;AJ Deshmukh;H Sridhar;A Ahmed;SJ Asirvatham;NN Ou;PA Noseworthy;AM Killu;SK Mulpuru;M Madhavan</p><p><strong><u>Abstract</u></strong><br>Direct oral anticoagulants (DOACs) can</p>]]></description><link>https://fahad.focalize.md/outcomes-of-direct-oral-anticoagulants-co-prescribed-with-common-interacting-medications/</link><guid isPermaLink="false">61cc6f6b78cb71e250fce2d4</guid><dc:creator><![CDATA[Fahad Shahid]]></dc:creator><pubDate>Wed, 29 Dec 2021 14:24:28 GMT</pubDate><content:encoded><![CDATA[<p><strong><u>JOURNAL</u></strong><br>The American journal of cardiology</p><p><strong><u>DOI</u></strong><br>10.1016/j.amjcard.2021.09.025</p><p><strong><u>Author(s)</u></strong><br>D Sanborn;A Sugrue;M Amin;R Mehta;M Farwati;AJ Deshmukh;H Sridhar;A Ahmed;SJ Asirvatham;NN Ou;PA Noseworthy;AM Killu;SK Mulpuru;M Madhavan</p><p><strong><u>Abstract</u></strong><br>Direct oral anticoagulants (DOACs) can potentially interact with multiple prescription medications. We examined the prevalence of co-prescription of DOACs with interacting medications and its impact on outcomes in patients with atrial fibrillation (AF). Patients with AF treated with a DOAC from 2010 to 2017 at the Mayo Clinic and co-prescribed medications that are inhibitors or inducers of the P-glycoprotein and/or Cytochrome P450 3A4 pathways were identified. The outcomes of stroke, transient ischemic attack, or systemic embolism, major bleeding, and minor bleeds were compared between patients with and without an enzyme inducer. Cox proportional hazards model was used to assess the association between interacting medications and outcomes. Of 8,576 patients with AF (mean age 70 &#xB1; 12 years, 35% female) prescribed a DOAC (38.6% apixaban, 35.8% rivaroxaban, 25.6% dabigatran), 2,610 (30.4%) were on at least 1 interacting agent: the majority were on an enzyme inhibitor (n = 2,592). Prescribed medications included non-dihydropyridine calcium channel blocker (n = 1,412; 16.5%), antiarrhythmic medication (n = 790; 9.2%), antidepressant (n = 659; 7.7%), antibiotic/antifungal (n = 77; 0.90%), antiepileptics (n = 17; 0.2%) and immunosuppressant medications (n = 19; 0.2%). Patients on an interacting medication were more likely to receive a lower dose of DOAC than indicated by the manufacturer&apos;s labeling (15.0% vs 11.4%, p &lt;0.0001). In multivariable analysis, co-prescription of an enzyme inhibitor was not associated with risk of any bleeding (hazard ratio 0.87 [0.71 to 1.05], p = 0.15) or stroke, transient ischemic attack, or systemic embolism (hazard ratio 0.82 [0.51 to 1.31], p = 0.39). In conclusion, DOACs are co-prescribed with medications with potential interactions in 30.4% of patients with AF. Co-prescription of DOACs and these drugs are not associated with increased risk of adverse embolic or bleeding outcomes in our cohort.</p><p><a href="https://www.focalize.md/find-journals/?a=W0K9130BEtb5a2zzBqSq">https://www.focalize.md/find-journals/?a=W0K9130BEtb5a2zzBqSq</a></p>]]></content:encoded></item><item><title><![CDATA[Draft Article for Newsletter]]></title><description><![CDATA[<p><strong><u>TITLE</u></strong><br>Outcomes of Direct Oral Anticoagulants Co-Prescribed with Common Interacting Medications.</p><p><strong><u>JOURNAL</u></strong><br>The American journal of cardiology</p><p><strong><u>DOI</u></strong><br>10.1016/j.amjcard.2021.09.025</p><p><strong><u>Author(s)</u></strong><br>D Sanborn;A Sugrue;M Amin;R Mehta;M Farwati;AJ Deshmukh;H Sridhar;A Ahmed;SJ Asirvatham;NN Ou;PA Noseworthy;AM</p>]]></description><link>https://fahad.focalize.md/draft-article-for-newsletter-12/</link><guid isPermaLink="false">61cc6f7878cb71e250fce2d8</guid><dc:creator><![CDATA[Fahad Shahid]]></dc:creator><pubDate>Wed, 29 Dec 2021 14:24:19 GMT</pubDate><content:encoded><![CDATA[<p><strong><u>TITLE</u></strong><br>Outcomes of Direct Oral Anticoagulants Co-Prescribed with Common Interacting Medications.</p><p><strong><u>JOURNAL</u></strong><br>The American journal of cardiology</p><p><strong><u>DOI</u></strong><br>10.1016/j.amjcard.2021.09.025</p><p><strong><u>Author(s)</u></strong><br>D Sanborn;A Sugrue;M Amin;R Mehta;M Farwati;AJ Deshmukh;H Sridhar;A Ahmed;SJ Asirvatham;NN Ou;PA Noseworthy;AM Killu;SK Mulpuru;M Madhavan</p><p><strong><u>Abstract</u></strong><br>Direct oral anticoagulants (DOACs) can potentially interact with multiple prescription medications. We examined the prevalence of co-prescription of DOACs with interacting medications and its impact on outcomes in patients with atrial fibrillation (AF). Patients with AF treated with a DOAC from 2010 to 2017 at the Mayo Clinic and co-prescribed medications that are inhibitors or inducers of the P-glycoprotein and/or Cytochrome P450 3A4 pathways were identified. The outcomes of stroke, transient ischemic attack, or systemic embolism, major bleeding, and minor bleeds were compared between patients with and without an enzyme inducer. Cox proportional hazards model was used to assess the association between interacting medications and outcomes. Of 8,576 patients with AF (mean age 70 &#xB1; 12 years, 35% female) prescribed a DOAC (38.6% apixaban, 35.8% rivaroxaban, 25.6% dabigatran), 2,610 (30.4%) were on at least 1 interacting agent: the majority were on an enzyme inhibitor (n = 2,592). Prescribed medications included non-dihydropyridine calcium channel blocker (n = 1,412; 16.5%), antiarrhythmic medication (n = 790; 9.2%), antidepressant (n = 659; 7.7%), antibiotic/antifungal (n = 77; 0.90%), antiepileptics (n = 17; 0.2%) and immunosuppressant medications (n = 19; 0.2%). Patients on an interacting medication were more likely to receive a lower dose of DOAC than indicated by the manufacturer&apos;s labeling (15.0% vs 11.4%, p &lt;0.0001). In multivariable analysis, co-prescription of an enzyme inhibitor was not associated with risk of any bleeding (hazard ratio 0.87 [0.71 to 1.05], p = 0.15) or stroke, transient ischemic attack, or systemic embolism (hazard ratio 0.82 [0.51 to 1.31], p = 0.39). In conclusion, DOACs are co-prescribed with medications with potential interactions in 30.4% of patients with AF. Co-prescription of DOACs and these drugs are not associated with increased risk of adverse embolic or bleeding outcomes in our cohort.</p><p><a href="https://www.focalize.md/find-journals/?a=W0K9130BEtb5a2zzBqSq">https://www.focalize.md/find-journals/?a=W0K9130BEtb5a2zzBqSq</a></p><hr><p><strong><u>TITLE</u></strong><br>Meta-Analysis of Randomized Clinical Trials Comparing the Impact of Implantable Loop Recorder Versus Usual Care After Ischemic Stroke for Detection of Atrial Fibrillation and Stroke Risk.</p><p><strong><u>JOURNAL</u></strong><br>The American journal of cardiology</p><p><strong><u>DOI</u></strong><br>10.1016/j.amjcard.2021.09.013</p><p><strong><u>Author(s)</u></strong><br>D Ko;Q Dai;DB Flynn;NA Bosch;RH Helm;KM Monahan;C Andersson;CD Anderson;AJ Walkey</p><p><strong><u>Abstract</u></strong><br>Implantable loop recorder (ILR) is recommended to detect subclinical atrial fibrillation (AF) after cryptogenic stroke; however, the clinical outcomes of this practice is unclear. We conducted a systematic review and meta-analysis of randomized controlled trials to evaluate 12-month AF detection, change in oral anticoagulation (OAC), and recurrent stroke in ILR versus usual care after ischemic stroke. We searched Medline, Embase, Web of Science, Cochrane Library for randomized controlled trials comparing ILR with usual care after any ischemic stroke. Primary outcomes were cumulative AF detection and recurrent stroke (ischemic or hemorrhagic) or transient ischemic attack over 12 months. Secondary outcome was OAC initiation. Meta-analysis was performed with Mantel-Haenszel pooled odds ratios (ORs) and random effects models. Of 200 identified articles, 3 trials were included (1,233 participants). Cryptogenic stroke and underlying AF included cryptogenic stroke only, stroke of known cause and underlying-AF included small or large vessel stroke only, and post embolic rhythm detection with implantable vs external monitoring included all ischemic strokes. The 12-month AF detection was 13% in the ILR group and 2.4% in controls. ILR was more likely to detect AF compared with usual care (OR 5.8, 95% confidence interval 3.2 to 10.2). Stroke or transient ischemic attack occurred in 7% with ILR and 9% with usual care (OR 0.8, 95% confidence interval 0.5 to 1.2). In patients with detected AF, 97% and 100% were started on OAC in cryptogenic stroke and underlying AF and post embolic rhythm detection with implantable vs external monitoring, respectively, compared with 68% in stroke of known cause and underlying-AF. In conclusion, ILR was superior to usual care in AF detection, but the relative low incidence of AF and the nondifferential risk of stroke between the ILR and usual care arms may suggest that most patients do not benefit from ILR implantation. Further studies are warranted to understand if patient selection can be improved to increase the diagnostic yield of ILR.</p><p><a href="https://www.focalize.md/find-journals/?a=XUK9130BEtb5a2zzBqSq">https://www.focalize.md/find-journals/?a=XUK9130BEtb5a2zzBqSq</a></p><hr>]]></content:encoded></item><item><title><![CDATA[Clinicopathological characteristics of IgG4-related lung disease.]]></title><description><![CDATA[<p><strong><u>JOURNAL</u></strong><br>BMC pulmonary medicine</p><p><strong><u>DOI</u></strong><br>10.1186/s12890-021-01781-3</p><p><strong><u>Author(s)</u></strong><br>J Liu;Y Liu;X Shen;Z He;T Yu;L Pang;X Jin;L Wang</p><p><strong><u>Abstract</u></strong><br>BACKGROUND Immunoglobulin G4-related lung disease (IgG4-RLD) is a rare entity. We retrospectively analyzed the clinical and histopathological characteristics of patients with pathologically confirmed</p>]]></description><link>https://fahad.focalize.md/clinicopathological-characteristics-of-igg4-related-lung-disease/</link><guid isPermaLink="false">61c99cb278cb71e250fce2b8</guid><dc:creator><![CDATA[Fahad Shahid]]></dc:creator><pubDate>Mon, 27 Dec 2021 11:00:02 GMT</pubDate><content:encoded><![CDATA[<p><strong><u>JOURNAL</u></strong><br>BMC pulmonary medicine</p><p><strong><u>DOI</u></strong><br>10.1186/s12890-021-01781-3</p><p><strong><u>Author(s)</u></strong><br>J Liu;Y Liu;X Shen;Z He;T Yu;L Pang;X Jin;L Wang</p><p><strong><u>Abstract</u></strong><br>BACKGROUND Immunoglobulin G4-related lung disease (IgG4-RLD) is a rare entity. We retrospectively analyzed the clinical and histopathological characteristics of patients with pathologically confirmed IgG4-RLD to improve the diagnosis rate and reduce the risk of misdiagnosis. METHODS We screened the pathological reports of 4838 patients with pulmonary surgery and/or biopsy specimens from April 2017 to April 2021 at Sun Yat-Sen Memorial Hospital affiliated with Sun Yat-Sen University, and specimens from 65 patients with suspected IgG4-RLD were subjected to immunohistochemical staining for IgG4 and IgG. Finally, 10 patients with definite IgG4-RLD that was pathologically confirmed were enrolled and analyzed. RESULTS The incidence of pathologically confirmed IgG4-RLD was 0.2% (10/4838). The ten patients had an average age of 59.7 years at diagnosis, and the male-to-female ratio was 9:1. The initial clinical manifestations were nonspecific, and cough was the most common symptom (4/10). More than one organ was involved in most patients (8/10), and mediastinal/hilar lymph node involvement was often observed (7/10). Serum IgG4 was analyzed in 6 patients and found to be elevated. Serum tumor marker levels were within the normal range or were slightly elevated. Computed tomography (CT) of the chest and/or 18F-fluorodeoxyglucose positron emission tomography-computed tomography (18F-FDG PET-CT) imaging revealed that 5 patients had a mixed type, 3 patients had the solid nodular type, and 2 patients had the bronchovascular type. All pulmonary masses and large nodules with solid patterns had spiculated margins and inhomogeneous enhancement with or without pleural indentation and a lobulated appearance. Abundant lymphoplasmacytic cell infiltration and fibrosis were observed in all patients. The expression of IgG4 and IgG was upregulated in the pulmonary sections. Seven patients were treated with glucocorticoids with or without additional immunosuppressants and responded well. CONCLUSIONS The results of our study suggest that multiple imaging findings, an elevated serum IgG4 concentration, and no significant increase in serum tumor biomarkers could provide diagnostic support for IgG4-RLD, especially for isolated IgG4-RLD or IgG4-RLD that includes other organ involvement that does not aid in establishing the diagnosis.</p>]]></content:encoded></item><item><title><![CDATA[Quality of life and asthma control in pregnant women with asthma.]]></title><description><![CDATA[<p><strong><u>JOURNAL</u></strong><br>BMC pulmonary medicine</p><p><strong><u>DOI</u></strong><br>10.1186/s12890-021-01797-9</p><p><strong><u>Author(s)</u></strong><br>N Fazel;M Kundi;E Jensen-Jarolim;IM Pali-Sch&#xF6;ll;A Kazemzadeh;H Esmaily;MF Abdizadeh;R Akbarzadeh;R Ahmadi;H Jabbari</p><p><strong><u>Abstract</u></strong><br>BACKGROUND Asthma is the most commonly occurring respiratory illness during pregnancy. Associations with complications of pregnancy and</p>]]></description><link>https://fahad.focalize.md/quality-of-life-and-asthma-control-in-pregnant-women-with-asthma/</link><guid isPermaLink="false">61c99cb078cb71e250fce2b4</guid><dc:creator><![CDATA[Fahad Shahid]]></dc:creator><pubDate>Mon, 27 Dec 2021 11:00:00 GMT</pubDate><content:encoded><![CDATA[<p><strong><u>JOURNAL</u></strong><br>BMC pulmonary medicine</p><p><strong><u>DOI</u></strong><br>10.1186/s12890-021-01797-9</p><p><strong><u>Author(s)</u></strong><br>N Fazel;M Kundi;E Jensen-Jarolim;IM Pali-Sch&#xF6;ll;A Kazemzadeh;H Esmaily;MF Abdizadeh;R Akbarzadeh;R Ahmadi;H Jabbari</p><p><strong><u>Abstract</u></strong><br>BACKGROUND Asthma is the most commonly occurring respiratory illness during pregnancy. Associations with complications of pregnancy and adverse perinatal outcome have been established. However, little is known about quality of life (QoL) in pregnant women with asthma and how it relates to asthma control particularly for Iran. OBJECTIVE To determine the relationship between asthma related QoL and asthma control and severity. METHODS We conducted a prospective study in pregnant women with asthma. We used the Asthma Control Questionnaire and the Asthma Quality of Life Questionnaire (AQLQ) and the guidelines of the Global Initiative for Asthma for assessment of asthma severity. RESULTS Among 1603 pregnant women, 34 were diagnosed with asthma. Of these 13 had intermittent, 10 mild, 8 moderate and 3 severe persistent asthma. There was a significant decrease of QoL with poorer asthma control (p&#x2009;=&#x2009;0.014). This decline could be due to limitations of activity in those with poorer asthma control, which is underlined by the significant decline of QoL with increasing asthma severity (p&#x2009;=&#x2009;0.024). CONCLUSION Although the majority of pregnant women with asthma had a favorable score in AQLQ, reduced QoL was related to increased asthma severity and poor asthma control. This underlines the importance of controlling asthma during pregnancy not only for the prevention of adverse pregnancy outcomes but also for the preservation of QoL.</p>]]></content:encoded></item><item><title><![CDATA[Chronic hypersensitivity pneumonitis is associated with an increased risk of venous thromboembolism: a retrospective cohort study.]]></title><description><![CDATA[<p><strong><u>JOURNAL</u></strong><br>BMC pulmonary medicine</p><p><strong><u>DOI</u></strong><br>10.1186/s12890-021-01794-y</p><p><strong><u>Author(s)</u></strong><br>M Sobiecka;M Szturmowicz;K Lewandowska;A Kowalik;E &#x141;y&#x17C;wa;K Zimna;I Bara&#x144;ska;L Jakubowska;J Ku&#x15B;;R Langfort;W Tomkowski</p><p><strong><u>Abstract</u></strong><br>BACKGROUND Idiopathic pulmonary fibrosis (IPF) and chronic hypersensitivity pneumonitis share commonalities</p>]]></description><link>https://fahad.focalize.md/chronic-hypersensitivity-pneumonitis-is-associated-with-an-increased-risk-of-venous-thromboembolism-a-retrospective-cohort-study-2/</link><guid isPermaLink="false">61c99cae78cb71e250fce2b0</guid><dc:creator><![CDATA[Fahad Shahid]]></dc:creator><pubDate>Mon, 27 Dec 2021 10:59:58 GMT</pubDate><content:encoded><![CDATA[<p><strong><u>JOURNAL</u></strong><br>BMC pulmonary medicine</p><p><strong><u>DOI</u></strong><br>10.1186/s12890-021-01794-y</p><p><strong><u>Author(s)</u></strong><br>M Sobiecka;M Szturmowicz;K Lewandowska;A Kowalik;E &#x141;y&#x17C;wa;K Zimna;I Bara&#x144;ska;L Jakubowska;J Ku&#x15B;;R Langfort;W Tomkowski</p><p><strong><u>Abstract</u></strong><br>BACKGROUND Idiopathic pulmonary fibrosis (IPF) and chronic hypersensitivity pneumonitis share commonalities in pathogenesis shifting haemostasis balance towards the procoagulant and antifibrinolytic activity. Several studies have suggested an increased risk of venous thromboembolism in IPF. The association between venous thromboembolism and chronic hypersensitivity pneumonitis has not been studied yet. METHODS A retrospective cohort study of IPF and chronic hypersensitivity pneumonitis patients diagnosed in single tertiary referral center between 2005 and 2018 was conducted. The incidence of symptomatic venous thromboembolism was evaluated. Risk factors for venous thromboembolism and survival among those with and without venous thromboembolism were assessed. RESULTS A total of 411 (259 IPF and 152 chronic hypersensitivity) patients were included (mean age 66.7&#x2009;&#xB1;&#x2009;8.4 vs 51.0&#x2009;&#xB1;&#x2009;13.3 years, respectively). There were 12 (4.6%) incident cases of venous thromboembolism in IPF and 5 (3.3%) in chronic hypersensitivity pneumonitis cohort. The relative risk (RR) of venous thromboembolism in chronic hypersensitivity pneumonitis was not significantly different to that found in patients with IPF (7.1 vs 11.8/1000 person-years, RR 1.661 95% CI 0.545-6.019, respectively). The treatment with systemic steroids (OR 5.38; 95% CI 1.65-18.8, p&#x2009;=&#x2009;0.006) and GAP stage 3 (OR 7.85; 95% CI 1.49-34.9; p&#x2009;=&#x2009;0.037) were significant risk factors for venous thromboembolism in IPF. Arterial hypertension and pulmonary hypertension significantly increased risk of venous thromboembolism in chronic hypersensitivity pneumonitis. There were no significant differences in survival between patients with and without venous thromboembolism. CONCLUSIONS The patients with chronic hypersensitivity pneumonitis have a marked increase in the risk of venous thromboembolism, similar to the patients with IPF. Venous thromboembolism does not affect the survival of patients with IPF and chronic hypersensitivity pneumonitis.</p>]]></content:encoded></item><item><title><![CDATA[Mathematical Modeling of Endemic Cholera Transmission.]]></title><description><![CDATA[<p><strong><u>JOURNAL</u></strong><br>The Journal of infectious diseases</p><p><strong><u>DOI</u></strong><br>10.1093/infdis/jiab472</p><p><strong><u>Author(s)</u></strong><br>DL Chao</p><p><strong><u>Abstract</u></strong><br>Mathematical modeling can be used to project the impact of mass vaccination on cholera transmission. Here, we discuss 2 examples for which indirect protection from mass vaccination needs to be considered. In the first,</p>]]></description><link>https://fahad.focalize.md/mathematical-modeling-of-endemic-cholera-transmission/</link><guid isPermaLink="false">61c5bef378cb71e250fce29f</guid><dc:creator><![CDATA[Fahad Shahid]]></dc:creator><pubDate>Fri, 24 Dec 2021 12:37:59 GMT</pubDate><content:encoded><![CDATA[<p><strong><u>JOURNAL</u></strong><br>The Journal of infectious diseases</p><p><strong><u>DOI</u></strong><br>10.1093/infdis/jiab472</p><p><strong><u>Author(s)</u></strong><br>DL Chao</p><p><strong><u>Abstract</u></strong><br>Mathematical modeling can be used to project the impact of mass vaccination on cholera transmission. Here, we discuss 2 examples for which indirect protection from mass vaccination needs to be considered. In the first, we show that nonvaccinees can be protected by mass vaccination campaigns. This additional benefit of indirect protection improves the cost-effectiveness of mass vaccination. In the second, we model the use of mass vaccination to eliminate cholera. In this case, a high population level of immunity, including contributions from infection and vaccination, is required to reach the &quot;herd immunity&quot; threshold needed to stop transmission and achieve elimination.</p>]]></content:encoded></item><item><title><![CDATA[test]]></title><description><![CDATA[<p>test</p>]]></description><link>https://fahad.focalize.md/test-2/</link><guid isPermaLink="false">61c5b8dd78cb71e250fce290</guid><dc:creator><![CDATA[Fahad Shahid]]></dc:creator><pubDate>Fri, 24 Dec 2021 12:11:45 GMT</pubDate><content:encoded><![CDATA[<p>test</p>]]></content:encoded></item><item><title><![CDATA[Cardiovascular morbidity in COPD: A study of the general population.]]></title><description><![CDATA[<p><strong><u>JOURNAL</u></strong><br>COPD</p><p><strong><u>DOI</u></strong><br>10.3109/15412550903499506</p><p><strong><u>Author(s)</u></strong><br>Lange|Peter|P|;Mogelvang|Rasmus|R|;Marott|Jacob Louis|JL|;Vestbo|J&#xF8;rgen|J|;Jensen|Jan Skov|JS|</p><p><strong><u>Abstract</u></strong><br>Although there are a number of studies on the coexistence of heart disease and COPD among patients acutely admitted to hospital, this</p>]]></description><link>https://fahad.focalize.md/cardiovascular-morbidity-in-copd-a-study-of-the-general-population/</link><guid isPermaLink="false">61c3300b78cb71e250fce284</guid><dc:creator><![CDATA[Fahad Shahid]]></dc:creator><pubDate>Wed, 22 Dec 2021 14:02:51 GMT</pubDate><content:encoded><![CDATA[<p><strong><u>JOURNAL</u></strong><br>COPD</p><p><strong><u>DOI</u></strong><br>10.3109/15412550903499506</p><p><strong><u>Author(s)</u></strong><br>Lange|Peter|P|;Mogelvang|Rasmus|R|;Marott|Jacob Louis|JL|;Vestbo|J&#xF8;rgen|J|;Jensen|Jan Skov|JS|</p><p><strong><u>Abstract</u></strong><br>Although there are a number of studies on the coexistence of heart disease and COPD among patients acutely admitted to hospital, this relationship has not been accurately described in the general population. Especially data on the prevalence of both reduced lung function and impaired left ventricular ejection fraction (LVEF) are sparse. We used data from the 4th examination of The Copenhagen City Heart Study, which comprises 5,890 individuals with data on pulmonary and cardiac symptoms, risk factors for cardiovascular diseases, pulmonary function tests, ECG and relevant medical history. Among the participants a randomly selected subgroup of 3,469 individuals underwent both spirometry and echocardiography. The participants were classified according to COPD stage using the international GOLD staging according to FEV(1) in % of predicted. The prevalence of COPD was 5.7% for mild COPD (GOLD stage 1), 9.4% for moderate COPD (GOLD stage 2) and 2.5% for severe and very severe COPD (GOLD stages 3+4). Individuals with COPD were older and had a higher prevalence of cardiovascular risk factors and a higher prevalence of cardiovascular diseases. Among the echocardiographical findings, only the presence of left ventricular hyperthrophy was significantly more frequent among individuals with COPD (17.7%) than among participants without COPD (12.1%.), yet this relationship was no longer significant after statistical adjustment for age and gender. In the general population, subjects with COPD have a higher prevalence of cardiovascular diseases and an unfavourable cardiovascular risk profile compared with individuals without COPD, but this was mainly related to higher age among the participants with COPD.</p>]]></content:encoded></item><item><title><![CDATA[just a test]]></title><description><![CDATA[<p>test</p>]]></description><link>https://fahad.focalize.md/just-a-test/</link><guid isPermaLink="false">61ae50de78cb71e250fce257</guid><dc:creator><![CDATA[Fahad Fellow 2]]></dc:creator><pubDate>Wed, 15 Dec 2021 16:54:44 GMT</pubDate><content:encoded><![CDATA[<p>test</p>]]></content:encoded></item><item><title><![CDATA[Draft Article for Newsletter]]></title><description><![CDATA[<p><strong><u>TITLE</u></strong><br>&quot;Big big renin*. Enzymatic and partial physical characterization of a new high molecular weight renin from normal human kidney.</p><p><strong><u>JOURNAL</u></strong><br>Circulation research</p><p><strong><u>DOI</u></strong><br>10.1161/01.res.41.4.7</p><p><strong><u>Author(s)</u></strong><br>JD Barrett;P Eggena;MP Sambhi</p><p><strong><u>Abstract</u></strong><br></p><p><a href="https://fahad.focalize.md/big-big-renin-enzymatic-and-partial-physical-characterization-of-a-new-high-molecular-weight-renin-from-normal-human-kidney/">https://fahad.focalize.md/big-big-renin-enzymatic-and-partial-physical-characterization-of-a-new-high-molecular-weight-renin-from-normal-human-kidney/</a></p><hr><p><strong><u>TITLE</u></strong><br>JNK2, a Newly-Identified</p>]]></description><link>https://fahad.focalize.md/draft-article-for-newsletter-4/</link><guid isPermaLink="false">6181421ea9889d15d7fbc7db</guid><dc:creator><![CDATA[Fahad Shahid]]></dc:creator><pubDate>Wed, 15 Dec 2021 16:53:13 GMT</pubDate><content:encoded><![CDATA[<p><strong><u>TITLE</u></strong><br>&quot;Big big renin*. Enzymatic and partial physical characterization of a new high molecular weight renin from normal human kidney.</p><p><strong><u>JOURNAL</u></strong><br>Circulation research</p><p><strong><u>DOI</u></strong><br>10.1161/01.res.41.4.7</p><p><strong><u>Author(s)</u></strong><br>JD Barrett;P Eggena;MP Sambhi</p><p><strong><u>Abstract</u></strong><br></p><p><a href="https://fahad.focalize.md/big-big-renin-enzymatic-and-partial-physical-characterization-of-a-new-high-molecular-weight-renin-from-normal-human-kidney/">https://fahad.focalize.md/big-big-renin-enzymatic-and-partial-physical-characterization-of-a-new-high-molecular-weight-renin-from-normal-human-kidney/</a></p><hr><p><strong><u>TITLE</u></strong><br>JNK2, a Newly-Identified SERCA2 Enhancer, Augments an Arrhythmic [Ca2+]SR Leak-Load Relationship.</p><p><strong><u>JOURNAL</u></strong><br>Circulation research</p><p><strong><u>DOI</u></strong><br>10.1161/CIRCRESAHA.120.318409</p><p><strong><u>Author(s)</u></strong><br>J Yan;DJ Bare;J DeSantiago;W Zhao;Y Mei;Z Chen;K Ginsburg;RJ Solaro;BM Wolska;DM Bers;SRW Chen;X Ai</p><p><strong><u>Abstract</u></strong><br>RATIONALE We recently discovered pivotal contributions of stress kinase JNK2 (c-Jun N-terminal kinase isoform 2) in increased risk of atrial fibrillation through enhanced diastolic sarcoplasmic reticulum (SR) calcium (Ca2+) leak via RyR2 (ryanodine receptor isoform 2). However, the role of JNK2 in the function of the SERCA2 (SR Ca2+-ATPase), essential in maintaining SR Ca2+ content cycling during each heartbeat, is completely unknown. OBJECTIVE To test the hypothesis that JNK2 increases SERCA2 activity SR Ca2+ content and exacerbates an arrhythmic SR Ca2+ content leak-load relationship. METHODS AND RESULTS We used confocal Ca2+ imaging in myocytes and HEK-RyR2 (ryanodine receptor isoform 2-expressing human embryonic kidney 293 cells) cells, biochemistry, dual Ca2+/voltage optical mapping in intact hearts from alcohol-exposed or aged mice (where JNK2 is activated). We found that JNK2, but not JNK1 (c-Jun N-terminal kinase isoform 1), increased SERCA2 uptake and consequently elevated SR Ca2+ content load. JNK2 also associates with and phosphorylates SERCA2 proteins. JNK2 causally enhances SERCA2-ATPase activity via increased maximal rate, without altering Ca2+ affinity. Unlike the CaMKII (Ca2+/calmodulin-dependent kinase II)-dependent JNK2 action in SR Ca2+ leak, JNK2-driven SERCA2 function was CaMKII independent (not prevented by CaMKII inhibition). With CaMKII blocked, the JNK2-driven SR Ca2+ loading alone did not significantly raise leak. However, with JNK2-CaMKII-driven SR Ca2+ leak present, the JNK2-enhanced SR Ca2+ uptake limited leak-induced reduction in SR Ca2+, normalizing Ca2+ transient amplitude, but at a higher arrhythmogenic SR Ca2+ leak. JNK2-specific inhibition completely normalized SR Ca2+ handling, attenuated arrhythmic Ca2+ activities, and alleviated atrial fibrillation susceptibility in aged and alcohol-exposed myocytes and intact hearts. CONCLUSIONS We have identified a novel JNK2-induced activation of SERCA2. The dual action of JNK2 in CaMKII-dependent arrhythmic SR Ca2+ leak and a CaMKII-independent uptake exacerbates atrial arrhythmogenicity, while helping to maintain normal levels of Ca2+ transients and heart function. JNK2 modulation may be a novel therapeutic target for atrial fibrillation prevention and treatment.</p><p><a href="https://fahad.focalize.md/jnk2-a-newly-identified-serca2-enhancer-augments-an-arrhythmic-ca2-sr-leak-load-relationship/">https://fahad.focalize.md/jnk2-a-newly-identified-serca2-enhancer-augments-an-arrhythmic-ca2-sr-leak-load-relationship/</a></p><hr>]]></content:encoded></item><item><title><![CDATA[Frequent Undetected Ward-Based Methicillin-Resistant Staphylococcus aureus Transmission Linked to Patient Sharing Between Hospitals.]]></title><description><![CDATA[<p><strong><u>JOURNAL</u></strong><br>Clinical infectious diseases : an official publication of the Infectious Diseases Society of America</p><p><strong><u>DOI</u></strong><br>10.1093/cid/cix901</p><p><strong><u>Author(s)</u></strong><br>O Tosas Auguet;RA Stabler;J Betley;MD Preston;M Dhaliwal;M Gaunt;A Ioannou;N Desai;T Karadag;R Batra;JA Otter;H Marbach;TG Clark;JD Edgeworth</p>]]></description><link>https://fahad.focalize.md/frequent-undetected-ward-based-methicillin-resistant-staphylococcus-aureus-transmission-linked-to-patient-sharing-between-hospitals/</link><guid isPermaLink="false">618143b5a9889d15d7fbc7df</guid><dc:creator><![CDATA[Fahad Shahid]]></dc:creator><pubDate>Wed, 15 Dec 2021 16:44:13 GMT</pubDate><content:encoded><![CDATA[<p><strong><u>JOURNAL</u></strong><br>Clinical infectious diseases : an official publication of the Infectious Diseases Society of America</p><p><strong><u>DOI</u></strong><br>10.1093/cid/cix901</p><p><strong><u>Author(s)</u></strong><br>O Tosas Auguet;RA Stabler;J Betley;MD Preston;M Dhaliwal;M Gaunt;A Ioannou;N Desai;T Karadag;R Batra;JA Otter;H Marbach;TG Clark;JD Edgeworth</p><p><strong><u>Abstract</u></strong><br>Background Recent evidence suggests that hospital transmission of methicillin-resistant Staphylococcus aureus (MRSA) is uncommon in UK centers that have implemented sustained infection control programs. We investigated whether a healthcare-network analysis could shed light on transmission paths currently sustaining MRSA levels in UK hospitals. Methods A cross-sectional observational study was performed in 2 National Health Service hospital groups and a general district hospital in Southeast London. All MRSA patients identified at inpatient, outpatient, and community settings between 1 November 2011 and 29 February 2012 were included. We identified genetically defined MRSA transmission clusters in individual hospitals and across the healthcare network, and examined genetic differentiation of sequence type (ST) 22 MRSA isolates within and between hospitals and inpatient or outpatient and community settings, as informed by average and median pairwise single-nucleotide polymorphisms (SNPs) and SNP-based proportions of nearly identical isolates. Results Two hundred forty-eight of 610 (40.7%) MRSA patients were linked in 90 transmission clusters, of which 27 spanned multiple hospitals. Analysis of a large 32 patient ST22-MRSA cluster showed that 26 of 32 patients (81.3%) had multiple contacts with one another during ward stays at any hospital. No residential, outpatient, or significant community healthcare contacts were identified. Genetic differentiation between ST22 MRSA inpatient isolates from different hospitals was less than between inpatient isolates from the same hospitals (P &#x2264; .01). Conclusions There is evidence of frequent ward-based transmission of MRSA brought about by frequent patient admissions to multiple hospitals. Limiting in-ward transmission requires sharing of MRSA status data between hospitals.</p>]]></content:encoded></item><item><title><![CDATA[Draft Article for Newsletter]]></title><description><![CDATA[<p><strong><u>TITLE</u></strong><br>Oral Immunotherapy With Human Secretory Immunoglobulin A Improves Survival in the Hamster Model of Clostridioides difficile Infection.</p><p><strong><u>JOURNAL</u></strong><br>The Journal of infectious diseases</p><p><strong><u>DOI</u></strong><br>10.1093/infdis/jiab087</p><p><strong><u>Author(s)</u></strong><br>EF Chiari;W Weiss;MR Simon;ST Kiessig;M Pulse;SC Brown;HR Gerding;M Mandago;K Gisch;C</p>]]></description><link>https://fahad.focalize.md/draft-article-for-newsletter-5/</link><guid isPermaLink="false">618143e4a9889d15d7fbc7eb</guid><dc:creator><![CDATA[Fahad Shahid]]></dc:creator><pubDate>Mon, 06 Dec 2021 17:42:23 GMT</pubDate><content:encoded><![CDATA[<p><strong><u>TITLE</u></strong><br>Oral Immunotherapy With Human Secretory Immunoglobulin A Improves Survival in the Hamster Model of Clostridioides difficile Infection.</p><p><strong><u>JOURNAL</u></strong><br>The Journal of infectious diseases</p><p><strong><u>DOI</u></strong><br>10.1093/infdis/jiab087</p><p><strong><u>Author(s)</u></strong><br>EF Chiari;W Weiss;MR Simon;ST Kiessig;M Pulse;SC Brown;HR Gerding;M Mandago;K Gisch;C von Eichel-Streiber</p><p><strong><u>Abstract</u></strong><br>Coadministration of human secretory IgA (sIgA) together with subtherapeutic vancomycin enhanced survival in the Clostridioides difficile infection (CDI) hamster model. Vancomycin (5 or 10 mg/kg &#xD7; 5 days) plus healthy donor plasma sIgA/monomeric IgA (TID &#xD7; 21 days) or hyperimmune sIgA/monomeric IgA (BID &#xD7; 13 days) enhanced survival. Survival was improved compared to vancomycin alone, P = .018 and .039 by log-rank Mantel-Cox, for healthy and hyperimmune sIgA, respectively. Passive immunization with sIgA (recombinant human secretory component plus IgA dimer/polymer from pooled human plasma) can be administered orally and prevents death in a partially treated CDI hamster model.</p><p><a href="https://fahad.focalize.md/oral-immunotherapy-with-human-secretory-immunoglobulin-a-improves-survival-in-the-hamster-model-of-clostridioides-difficile-infection/">https://fahad.focalize.md/oral-immunotherapy-with-human-secretory-immunoglobulin-a-improves-survival-in-the-hamster-model-of-clostridioides-difficile-infection/</a></p><hr><p><strong><u>TITLE</u></strong><br>The Mosaic mtr Locus as Major Genetic Determinant of Azithromycin Resistance of Neisseria gonorrhoeae-Germany, 2018.</p><p><strong><u>JOURNAL</u></strong><br>The Journal of infectious diseases</p><p><strong><u>DOI</u></strong><br>10.1093/infdis/jiab091</p><p><strong><u>Author(s)</u></strong><br>S Banhart;R Selb;S Oehlmann;J Bender;S Buder;K Jansen;D Heuer</p><p><strong><u>Abstract</u></strong><br>Within the German Gonococcal Resistance Network&apos;s (GORENET) Neisseria gonorrhoeae (NG) sample collection, azithromycin-resistant NG isolates increased from 4.3% in 2016 to 9.2% in 2018. We aim to understand this observed increase using whole genome sequencing of NG isolates combined with epidemiological and clinical data. Reduced susceptibility to azithromycin in 2018 was predominately clonal (NG multiantigen sequence typing G12302) and could mainly be attributed to the recently described mosaic-like mtr locus. Our data suggest that, together with horizontal gene transfer of resistance determinants and well-established point mutations, international spread of resistant lineages plays a major role regarding azithromycin resistance in Germany.</p><p><a href="https://fahad.focalize.md/the-mosaic-mtr-locus-as-major-genetic-determinant-of-azithromycin-resistance-of-neisseria-gonorrhoeae-germany-2018/">https://fahad.focalize.md/the-mosaic-mtr-locus-as-major-genetic-determinant-of-azithromycin-resistance-of-neisseria-gonorrhoeae-germany-2018/</a></p><hr>]]></content:encoded></item></channel></rss>